Thursday, August 9, 2018

Ambys Medicines Snags $140M

Redwood City-based Ambys Medicines, a biotechnology firm focused on people with serious liver disease, has raised $140M in funding, for its efforts to develop medicines for serious liver diseases. The company said the funding included $60M in a Series A funding from Third Rock Ventures and Takeda, along with an additional $80M from Takeda as part of a strategic partnership. Ambys said it is developing a number of treatments for chronic liver diseases, including cell therapy for hepatocyte transplantation, gene therapy for liver regeneration, and drug therapy to replace lost protein function. Jeffrey Tong, Ph.D. is interim Chief Executive Officer of Ambys. More information »